SCHEMBL322573

SCHEMBL322573

CC(C)(C)[PH3+].F[B-](F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL534110 1.00
SCHEMBL1717775 0.79 TSHR (0.40)
SCHEMBL1717892 0.76
Tert-Butanol SCHEMBL384629 0.74
SCHEMBL15955554 0.74
SCHEMBL14244290 0.73 TSHR (0.67)
Chloromethane SCHEMBL23414945 0.72 TSHR (0.30)
SCHEMBL31474834 0.72
SCHEMBL12474236 0.72
SCHEMBL25276824 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023135609-A1 THERMALLY ACTIVATED DELAYED FLUORESCENT SOLVENT-FREE ORGANIC LIQUID COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-07-20 WO claimed
WO-2025229494-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-11-06 WO disclosed
US-12146087-B2 Compound and organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2024-11-19 US disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
EP-3890487-B1 HERBICIDAL COMPOSITIONS SYNGENTA PARTICIPATIONS AG (CH) 2024-06-12 EP disclosed
CN-114426558-B Fused ring compound containing three boron atoms, preparation method thereof and electroluminescent device 中国科学院长春应用化学研究所 2024-05-31 CN disclosed
CN-112638380-B Cerebellar protein (CRBN) ligands 达纳-法伯癌症研究所有限公司 2024-05-24 CN disclosed
EP-3737667-B1 HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2024-04-03 EP disclosed
EP-4334301-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS University College Cardiff Consultants Limited (GB) 2024-03-13 EP disclosed
WO-2024050513-A1 PHENOTHIAZINES FOR TREATING MITOCHONDRIAL DISEASE ACUREX BIOSCIENCES CORPORATION (US) 2024-03-07 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2009001089-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-12-31 WO disclosed
WO-2008134338-A1 NOVEL PROCESSES OF MAKING HYDROXY-1-AZO-DERIVATIVES AS TPO MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-06 WO disclosed
WO-2008047109-A1 THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-24 WO disclosed
WO-2008016184-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-07 WO disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed
EP-1841504-A2 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS Brystol-Myers Squibb Company (US) 2007-10-10 EP disclosed
EP-1730152-A2 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2006-12-13 EP disclosed
WO-2006076575-A2 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-07-20 WO disclosed
WO-2005095409-A2 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2005-10-13 WO disclosed